Related Experiment Video
Updated: May 28, 2026
10:06
An Efficient Method for Adenovirus Production
Published on: June 10, 2021
Adenoviral producer cells.
Imre Kovesdi1, Susan J Hedley1
1VectorLogics, Inc., 550 11th Street South, Birmingham, AL35294, USA.
Viruses
|October 14, 2011
Summary
Adenovirus (Ad) vectors require specific producer cell lines for gene therapy applications. This review covers historical and novel cell lines, addressing challenges like replication-competent adenovirus contamination.
Area of Science:
- Biotechnology
- Molecular Biology
- Virology
Background:
- Adenovirus (Ad) vectors, particularly serotype 5, are valuable for gene therapy, vaccines, and virotherapy.
- Therapeutic applications necessitate modifications to the wild-type Ad genome, often requiring specialized producer cell lines for viral production.
- Producer cell lines provide trans-complementation, either through integrated viral sequences or natural cellular complementation.
Purpose of the Study:
- To review producer cell lines used for non-replicating adenoviral vectors.
- To discuss the historical HEK293 cell line and its limitations, including replication-competent adenovirus (RCA) contamination.
- To explore novel cell lines for advanced Ad vectors and alternative serotypes.
Main Methods:
- Literature review focusing on producer cell lines for adenoviral vectors.
- Analysis of historical context, starting with the HEK293 cell line.
- Discussion of challenges and advancements in cell line development for Ad vectors.
Main Results:
- The HEK293 cell line was foundational for first-generation Ad vectors but poses RCA contamination risks.
- Development of alternative cell lines addresses the limitations of HEK293.
- Emerging cell lines cater to more complex Ad vector designs and diverse serotypes.
Conclusions:
- Producer cell lines are critical for the safe and efficient production of modified adenoviral vectors.
- Ongoing research focuses on developing improved cell lines to mitigate risks and expand therapeutic applications.
- Advancements in cell line technology are crucial for the future of adenoviral vector-based therapies.
Related Concept Videos
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...